Biomedical Research
Online ISSN : 1880-313X
Print ISSN : 0388-6107
ISSN-L : 0388-6107
Communications
Prevalence of low-penetrant germline TP53 D49H mutation in Japanese cancer patients
Ken YAMAGUCHI, Kenichi URAKAMI, Takeshi NAGASHIMA, Yuji SHIMODA, Shumpei OHNAMI, Sumiko OHNAMI, Keiichi OHSHIMA, Tohru MOCHIZUKI, Keiichi HATAKEYAMA, Masakuni SERIZAWA, Yasuto AKIYAMA, Kouji MARUYAMA, Hirohisa KATAGIRI, Yuji ISHIDA, Kaoru TAKAHASHI, Seiichiro NISHIMURA, Masanori TERASHIMA, Taiichi KAWAMURA, Yusuke KINUGASA, Yushi YAMAKAWA, Tetsuro ONITSUKA, Yasuhisa OHDE, Takashi SUGINO, Ichiro ITO, Hiroyuki MATSUBAYASHI, Yasue HORIUCHI, Maki MIZUGUCHI, Mutsumi YAMAZAKI, Kengo INOUE, Kimiko WAKAMATSU, Misato SUGIYAMA, Katsuhiko UESAKA, Masatoshi KUSUHARA
Author information
JOURNAL FREE ACCESS

2016 Volume 37 Issue 4 Pages 259-264

Details
Download PDF (227K)
Download citation RIS

(compatible with EndNote, Reference Manager, ProCite, RefWorks)

BIB TEX

(compatible with BibDesk, LaTeX)

Text
How to download citation
Contact us
Abstract

Using whole exome sequencing data obtained from 1,685 Japanese cancer patients, we examined genetic variations of germline TP53 and found 10 types of non-synonymous single nucleotide variants. In the present study, we focused on 6 patients with germline D49H mutation located in the transactivation domain 2 of p53 protein, since the mutation seemed to be prevalent in cancer patients and to be pathogenic. According to the initial survey for family history of the proband with the germline TP53 D49H mutation, one osteosarcoma patient and his pedigree fulfill the criteria for Li-Fraumeni-like syndrome and the 2009 Chompret criteria for germline TP53 mutation screening. Since this patient possesses double germline mutations of TP53 D49H and A159D, further studies are required to evaluate contribution of the D49H mutation in this morbidity. The remaining 5 patients had family histories of cancer, but none fulfills the criteria either for the Li-Fraumeni/Li-Fraumeni-like syndromes or the 2009 Chompret criteria for germline TP53 mutation screening. It is possible to postulate that the germline TP53 D49H mutation is likely to be low-penetrant in some pedigrees. The present study also indicates that the survey for the germline TP53 mutation plays an important role in clinical practice as it will prevent mistaking cancer patients with unusual heredities for sporadic cases.

Content from these authors
© 2016 Biomedical Research Press
Previous article Next article
Favorites & Alerts

Recently viewed articles
Share this page
feedback
 Top